9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Celltrion, Inc. (068270.KS)

KSE - KSE Delayed price. Currency in KRW

Add to watchlist

176,600.00

-800.00

(-0.45%)

At close: 03:30PM KST

Press releases

PR Newswire
ZYMFENTRA™(infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab, now commercially available in the U.S.
Celltrion USA announced today the availability of a ZYMFENTRA™ (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab.[1] ZYMFENTRA is the first and only subcutaneous infliximab approved by the U.S. Food and Drug Administration (FDA) in 2023.
PR Newswire
Celltrion USA completes submission of Biologics License Application (BLA) to U.S. FDA for CT-P39, an interchangeable biosimilar candidate of XOLAIR® (omalizumab)
Celltrion USA today announced that the company has submitted a Biologics License Application (BLA) for CT-P39, an interchangeable biosimilar candidate to XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA).[1]
PR Newswire
Celltrion USA completes submission of Biologics License Application for CT-P47, a biosimilar candidate of ACTEMRA® (tocilizumab)
Celltrion USA today announced the submission of Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for CT-P47, a biosimilar candidate of the reference product ACTEMRA® (tocilizumab)[1].